Avonex
(Interferon beta-1a)Phase 3Small molecule
EMD SeronoInterferon beta-1a is used to treat multiple sclerosis, a disease where the immune system attacks nerve cells in the brain and spinal cord, causing problems with movement and other functions. It helps reduce the frequency and severity of relapses in relapsing-remitting multiple sclerosis.[1] Avonex is currently being investigated across 20 indications[3], with its most advanced program in Phase 3.[1]
Avonex is one of 491 small molecule programs targeting Adult Acute Respiratory Distress Syndrome. It is currently in Phase 3.
20
Indications
62
Total Trials
3
Active Trials
490
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 20 indications
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Avonex
EMD SeronoPhase 3
Spikevax
ModernaPreclinical
Bnt162b2
BioNTechPreclinical
COVID-19 Vaccine
ModernaPreclinical
Biaxin
AbbViePreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Singulair
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Sclerosis22 trials
Show 19 more trials
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
Completed·—··NCT00490906·60 enrolled
COVID-195 trials
Adaptive COVID-19 Treatment Trial 3 (ACTT-3)
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT04492475·969 enrolled
Relapsing-Remitting Multiple Sclerosis4 trials
Tics2 trials
23 more indications
Pneumonia1 trial
Stroke1 trial
Safety Study of Interferon Beta 1a to for Acute Stroke
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT00097318·60 enrolled
Acute Respiratory Distress Syndrome1 trial
RRMS1 trial
Safety and Efficacy1 trial
Chronic Hepatitis1 trial
ESS1 trial
Common Cold1 trial
Treatment1 trial
Induction Therapy1 trial
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
Withdrawn·MMidAmerica Neuroscience Research Foundation at Rowe Neurology Institute·Phase 4·NCT00037115
Cell Therapy1 trial
Side Effects1 trial
Labor1 trial
Chronic Inflammatory Demyelinating Polyradiculoneuropathy1 trial
Patient Satisfaction1 trial
Quality of Life1 trial
Nasopharyngeal Carcinoma1 trial
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
Recruiting·GGerman Society for Pediatric Oncology and Hematology GPOH gGmbH·Phase 2·NCT06019130·57 enrolled
Biomarkers1 trial
Corona Virus Infection1 trial
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Completed·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 3·NCT04315948·1,552 enrolled
Unspecified5 trials
Phase I BP Interferon (IFN) Beta-001
Completed·—·Phase 1·NCT02515695·12 enrolled
Regulatory
FDA Approval Timeline[4]
May 17, 1996
AVONEX
BLA BLA103628
Mar 7, 2002
REBIF
BLA BLA103780
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Interferon beta-1a. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Interferon Alpha/beta Receptor Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company